Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience
Margaret E Heffernan, Suzanne M Garland, Mark A Kane
Sexual Health | CSIRO PUBLISHING | Published : 2010
BACKGROUND: Worldwide, prophylactic vaccines against two major human cancers are now commercially available: hepatitis B virus (HBV) vaccines (first licensed in 1982) against primary hepatocellular carcinoma and human papillomavirus (HPV) vaccines (first licensed 2006) against cervical cancer. Initial implementation strategies for HBV vaccination were not successful in preventing disease in the community: it took 15 years for significant global reduction in the burden of this disease. METHODS: We compare and contrast HBV vaccine experiences to challenges for successful global HPV vaccination strategies, and make recommendations accordingly. RESULTS: Lessons from HBV immunisation for successf..View full abstract
MEH has received travel support from CSL and GlaxoSmithKline (GSK) to attend two international HPV conferences. SMG has received advisory board fees and grant support from CSL and GSK, and lecture fees from Merck and GSK; in addition, she has received funding through her institution to conduct HPV vaccine studies for MSD and GSK. SMG is a member of the Merck Global Advisory Board as well as of the Merck Scientific Advisory Committee for HPV. MK is on the Merck Global Advisory Board for HPV and has received honoraria for speaking from both Merck and GSK.